Medicaid; create provisions effecting parity in the prescription of pain medication.
Summary
Senate Bill 2388 would require the Mississippi Division of Medicaid, when creating and maintaining its preferred drug list, to treat certain nonopioid pain medications and certain nonstatin cardiovascular medications no less favorably than comparable opioid, narcotic, or other cardiovascular drugs. For pain treatment, the bill bars Medicaid from disadvantaging FDA-approved nonopioid pain drugs by placing them on a nonpreferred tier or imposing more restrictive prior authorization, step therapy, or other utilization controls than those applied to opioid or narcotic pain drugs. The rule applies immediately upon FDA approval, even before the drug is formally reviewed for the preferred drug list.
The bill also creates a similar parity requirement for nonstatin medications with a unique indication to reduce major cardiovascular events in primary and secondary prevention patients. Medicaid may not make these drugs less favorable than other cardiovascular drugs on the preferred drug list, including through more restrictive clinical review, prior authorization, or step therapy. Both provisions apply not only to Medicaid’s direct drug coverage decisions but also to drugs provided through managed care organization contracts. The act is set to take effect on July 1, 2025.
Impact
SB 2388 would amend how the Mississippi Division of Medicaid administers its preferred drug list by imposing statutory parity rules for specified nonopioid pain medications and certain nonstatin cardiovascular drugs. In practice, it limits the agency’s discretion to place these drugs on nonpreferred tiers or to apply stricter utilization management than the least restrictive controls used for comparable opioid, narcotic, or cardiovascular medications. The bill would affect Medicaid coverage policy, formulary design, prior authorization practices, step therapy requirements, and managed care contracts.
Sentiment
The available voting history suggests strong support for the bill: the Senate passed it on February 5, 2025 by a 51-0 vote. No committee transcript is available, but the unanimous Senate vote indicates broad agreement with the bill’s goal of improving access to certain nonopioid and cardiovascular medications within Medicaid. The caption and text frame the measure as a patient-access and coverage-parity bill rather than a cost-containment measure.
Contention
No recorded committee debate is available, and the floor vote was unanimous, so there is no documented opposition in the provided materials. Potential points of policy tension inherent in the bill include reduced flexibility for Medicaid to use preferred drug list tools such as tiering, prior authorization, and step therapy to manage costs or utilization. Any concern would likely come from administrators or insurers focused on formulary control, while supporters would favor the bill’s emphasis on access to nonopioid pain treatments and nonstatin cardiovascular therapies.